After her second round of chemo, with her ovarian cancer in remission, Marie started taking a mixed-media art class. Around this same time, Marie began taking maintenance treatment as part of the NOVA study. As the weeks turned to months without cancer recurring Marie’s art became her passion. Maintenance treatment with ZEJULA has given Marie time to create and exhibit her work at galleries. Her proudest composition is shared with you here.
ZEJULA is the first and only once-daily PARP inhibitor for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.1-3
More Time for More Women1
ZEJULA increased progression-free survival (PFS) for women with recurrent ovarian cancer following complete or partial response to platinum-based chemotherapy in a randomized, placebo-controlled phase 3 trial.1,4
Median PFS in the Pivotal Trial
- At the time of the PFS analysis, limited overall survival data were available, with 17% of survival events occurring in the study (HR=0.73; 95% CI, 0.48-1.13; P=0.15).1,5
BRCA, breast cancer susceptibility gene; CI, confidence interval; gBRCAmut, germline BRCA mutated; HR, hazard ratio; non-gBRCAmut, not germline BRCA mutated; NS, not significant; PARP, poly(ADP-ribose) polymerase; PFS, progression-free survival.
Get the latest news about ZEJULA
Sign up below